ReviewActa neurologica Scandinavica2022
Blood biomarkers of peripheral neuropathy.
Review in Acta neurologica Scandinavica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Genome-wide meta-analysis identifies genetic risk loci for mono- and polyneuropathies in 983 477 individuals.Human molecular genetics · 2026Pooled it
- Systematic review of translational insights: Neuromodulation in animal models for Diabetic Peripheral Neuropathy.PloS one · 2024Pooled it
- Metabolic Dysregulation, Inflammation, and Median Nerve Dysfunction in Patients with Type 2 Diabetes Mellitus with Carpal Tunnel Syndrome.International journal of molecular sciences · 2026Article
- Investigating the role of serum NfL, FGF21, NCAM1 and GDF15 as disease biomarkers for Charcot-Marie-Tooth type 2A.Scientific reports · 2026Article
- Neuroprotective effect of low-intensity ultrasound against diabetic neuropathy.Irish journal of medical science · 2026Article
- Plasma Mucin-1 as a Potential Biomarker for Diabetic Peripheral Neuropathy in Type 2 Diabetes.Biomolecules · 2026Article
- Polyneuropathy in hereditary and wildtype transthyretin amyloidosis, comparison of key clinical features and red flags.Scientific reports · 2025Article
- Protocol for a Prospective Cohort Study on Determinants of Outcomes in Lumbar Radiculopathy Surgery.Healthcare (Basel, Switzerland) · 2025Article
- Digital biomechanical assessment of gait in patients with peripheral neuropathies.Journal of neuroengineering and rehabilitation · 2025Article
- Cardiovascular Health and Biomarkers of Neurodegenerative Disease in Older Adults.JAMA network open · 2025Article
- Serum potassium level is associated with serum neurofilament light chain in American adult population: a cross-sectional analysis of the 2013-2014 National Health and Nutrition Examination Survey.Frontiers in aging neuroscience · 2025Article
- Biomarkers and Novel Therapies of Diabetic Neuropathy: An Updated Review.Current pharmaceutical biotechnology · 2025Review
- Serum neurofilament light chain levels in patients with small-fiber neuropathy.Journal of neuromuscular diseases · 2024Article
- Serum neurofilament light chain levels in patients with small-fiber neuropathy.Journal of neuromuscular diseases · 2024Article
- TLR-4: a promising target for chemotherapy-induced peripheral neuropathy.Molecular biology reports · 2024Review
- Phase Angle of Bioelectrical Impedance Analysis as an Indicator for Diabetic Polyneuropathy in Type 2 Diabetes Mellitus.The Journal of clinical endocrinology and metabolism · 2024Observational
- Update on Biomarkers of Chronic Inflammatory Processes Underlying Diabetic Neuropathy.International journal of molecular sciences · 2024Review
- Serum neurofilament light chain as a prognostic marker of all-cause mortality in a national sample of US adults.European journal of epidemiology · 2024Article
- p62/sequestosome-1 as a severity-reflecting plasma biomarker in Charcot-Marie-Tooth disease type 1A.Scientific reports · 2024Article
- Predictive Value of Combined HbA1c and Neutrophil-to-Lymphocyte Ratio for Diabetic Peripheral Neuropathy in Type 2 Diabetes.Medical science monitor : international medical journal of experimental and clinical research · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditionally, neurophysiology is the primary diagnostic and prognostic biomarker in peripheral neuropathy clinical practice; however, it may lack responsiveness in the context of slowly progressive neuropathies and where there is significant axonal damage. The development of ultrasensitive platforms for measuring serum proteins at the lower limit of detection of traditional ELISA techniques has transformed the field of blood biomarkers of peripheral neuropathy. A variety of blood biomarkers have been identified from inflammatory cytokines and apokines in diabetic neuropathy through to neuron-specific proteins such as neurofilament light chain, Schwann cell-specific proteins such as TMPRSS5 and microRNAs in other acquired and hereditary neuropathies. In this article, we review blood biomarkers of disease activity for the common subtypes of peripheral neuropathy including inflammatory demyelinating neuropathies, vasculitic neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy and Charcot-Marie-Tooth disease and related disorders including TTR amyloidosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.